Tower Research Capital (TRC)’s Crescent Biopharma CBIO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $31.7K | Buy |
+1,761
| New | +$34.4K | ﹤0.01% | 3131 |
|
|
2026
Q1 | – | Sell |
-409
| Closed | -$4.85K | – | 5279 |
|
|
2025
Q4 | $4.85K | Buy |
409
+209
| +105% | +$2.66K | ﹤0.01% | 4174 |
|
|
2025
Q3 | $2.38K | Buy |
+200
| New | +$2.65K | ﹤0.01% | 4635 |
|
|
2025
Q2 | – | Sell |
-94
| Closed | -$1.96K | – | 5373 |
|
|
2025
Q1 | $1.96K | Sell |
94
-102
| -52% | -$2.73K | ﹤0.01% | 4615 |
|
|
2024
Q4 | $4.87K | Buy |
+196
| New | +$5.34K | ﹤0.01% | 4383 |
|
|
2024
Q2 | – | Sell |
-236
| Closed | -$70.9K | – | 5807 |
|
|
2024
Q1 | $70.9K | Buy |
236
+207
| +714% | +$61.8K | ﹤0.01% | 2044 |
|
|
2023
Q4 | $6.8K | Sell |
29
-18
| -38% | -$2.8K | ﹤0.01% | 4695 |
|
|
2023
Q3 | $6.99K | Sell |
47
-39
| -45% | -$6.15K | ﹤0.01% | 4525 |
|
|
2023
Q2 | $15K | Sell |
86
-158
| -65% | -$26.5K | ﹤0.01% | 3656 |
|
|
2023
Q1 | $30K | Buy |
+244
| New | +$54.9K | ﹤0.01% | 2992 |
|
|
2022
Q4 | – | Sell |
-216
| Closed | -$12K | – | 6077 |
|
|
2022
Q3 | $12K | Buy |
216
+120
| +125% | +$8.62K | ﹤0.01% | 4340 |
|
|
2022
Q2 | $6K | Buy |
96
+76
| +380% | +$5.63K | ﹤0.01% | 4925 |
|
|
2022
Q1 | $2K | Sell |
20
-53
| -73% | -$6.22K | ﹤0.01% | 5552 |
|
|
2021
Q4 | $10K | Buy |
73
+22
| +43% | +$3.99K | ﹤0.01% | 4563 |
|
|
2021
Q3 | $11K | Sell |
51
-107
| -68% | -$22.7K | ﹤0.01% | 4224 |
|
|
2021
Q2 | $36K | Buy |
158
+68
| +76% | +$17.3K | ﹤0.01% | 3298 |
|
|
2021
Q1 | $27K | Buy |
90
+45
| +100% | +$16.1K | ﹤0.01% | 3638 |
|
|
2020
Q4 | $16K | Sell |
45
-361
| -89% | -$126K | ﹤0.01% | 4006 |
|
|
2020
Q3 | $125K | Buy |
406
+332
| +449% | +$127K | ﹤0.01% | 2965 |
|
|
2020
Q2 | $27K | Buy |
+74
| New | +$21K | ﹤0.01% | 3507 |
|
|
2020
Q1 | – | Sell |
-118
| Closed | -$62K | – | 3360 |
|
|
2019
Q4 | $62K | Sell |
118
-22
| -16% | -$11.9K | 0.01% | 1205 |
|
|
2019
Q3 | $61K | Buy |
140
+138
| +6,900% | +$88.8K | ﹤0.01% | 1657 |
|
|
2019
Q2 | $2K | Sell |
2
-12
| -86% | -$14.3K | ﹤0.01% | 3267 |
|
|
2019
Q1 | $18K | Buy |
+14
| New | +$16K | ﹤0.01% | 2322 |
|
|
2018
Q4 | – | Sell |
-17
| Closed | -$24K | – | 4016 |
|
|
2018
Q3 | $24K | Buy |
+17
| New | +$25.7K | ﹤0.01% | 2216 |
|
|
2018
Q2 | – | Sell |
-75
| Closed | -$122K | – | 3812 |
|
|
2018
Q1 | $122K | Buy |
75
+72
| +2,400% | +$150K | 0.01% | 1137 |
|
|
2017
Q4 | $4K | Buy |
+3
| New | +$3.97K | ﹤0.01% | 2987 |
|
|
2017
Q3 | – | Sell |
-60
| Closed | -$67K | – | 3921 |
|
|
2017
Q2 | $67K | Buy |
60
+51
| +567% | +$42.1K | 0.01% | 632 |
|
|
2017
Q1 | $5K | Buy |
9
+4
| +80% | +$2.46K | ﹤0.01% | 2194 |
|
|
2016
Q4 | $3K | Buy |
5
+3
| +150% | +$1.87K | ﹤0.01% | 3249 |
|
|
2016
Q3 | $2K | Buy |
+2
| New | +$1.53K | ﹤0.01% | 3077 |
|
|
2016
Q2 | – | Sell |
-10
| Closed | -$6K | – | 4625 |
|
|
2016
Q1 | $6K | Buy |
10
+1
| +11% | +$513 | ﹤0.01% | 2519 |
|
|
2015
Q4 | $5K | Sell |
9
-12
| -57% | -$7.95K | ﹤0.01% | 2973 |
|
|
2015
Q3 | $12K | Buy |
+21
| New | +$15.2K | ﹤0.01% | 2155 |
|
|
2015
Q2 | – | Hold |
0
| – | – | – | 4619 |
|
|
2015
Q1 | – | Hold |
0
| – | – | – | 4598 |
|
|
2014
Q4 | – | Sell |
-2
| Closed | -$1.56K | – | 4250 |
|
|
2014
Q3 | $1K | Buy |
+2
| New | +$1.62K | ﹤0.01% | 4087 |
|
|
2014
Q2 | – | Sell |
-8
| Closed | -$13K | – | 4265 |
|
|
2014
Q1 | $13K | Buy |
+8
| New | +$9.68K | ﹤0.01% | 2340 |
|
Other funds holding CBIO
FFM
LGM
FIS
BCM
NCM
Tower Research Capital (TRC)'s CBIO Position: Q2 2026 in Review
Tower Research Capital (TRC) opened a new position in Crescent Biopharma (CBIO) in Q2 2026: 1,761 shares worth $31.7K. The stake represents ﹤0.01% of the portfolio and ranks #3131 among its holdings. This is a return to the name: Tower Research Capital (TRC) previously reported a position in CBIO as recently as Q4 2025.
Tower Research Capital (TRC) first reported a position in CBIO in Q1 2014 and has held it in 36 quarters since. The position peaked at $125K in Q3 2020. 70 funds tracked by Wall St. Rank hold CBIO as of Q2 2026.
- Tower Research Capital (TRC) held 1,761 shares of Crescent Biopharma worth $31.7K as of Q2 2026.
- Crescent Biopharma was a new Tower Research Capital (TRC) position in Q2 2026.
- Crescent Biopharma made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3131 holding.
- Tower Research Capital (TRC) first reported a position in Crescent Biopharma in Q1 2014 and has held it in 36 quarters since.
- Tower Research Capital (TRC)'s Crescent Biopharma position peaked at $125K in Q3 2020.
- 70 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2026.
Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.